Figure 1
Figure 1. Long-term outcomes after transplantation of G-PBMCs (n = 81) or bone marrow (n = 91) from HLA-identical siblings after myeloablative conditioning.8 Kaplan-Meier estimates of OS among all patients (A), and among those with high-risk malignancies (B) and standard-risk malignancies (C); DFS among all patients (D), and among those with high-risk malignancies (E) and standard-risk malignancies (F). (G) OS and (J) DFS after exclusion of 47 patients transplanted for CML in chronic phase. Also shown are cumulative incidence curves of NRM (H), relapse (I), extensive chronic GVHD (K), and discontinuation of all immunosuppressive treatment (L; lower 2 curves). The competing risks of relapse and death are shown in the upper 2 curves. Also shown are the adjusted HRs for respective outcomes using marrow recipients as the reference group. Solid line indicates G-PBMC group; and hyphenated line, bone marrow group.

Long-term outcomes after transplantation of G-PBMCs (n = 81) or bone marrow (n = 91) from HLA-identical siblings after myeloablative conditioning. Kaplan-Meier estimates of OS among all patients (A), and among those with high-risk malignancies (B) and standard-risk malignancies (C); DFS among all patients (D), and among those with high-risk malignancies (E) and standard-risk malignancies (F). (G) OS and (J) DFS after exclusion of 47 patients transplanted for CML in chronic phase. Also shown are cumulative incidence curves of NRM (H), relapse (I), extensive chronic GVHD (K), and discontinuation of all immunosuppressive treatment (L; lower 2 curves). The competing risks of relapse and death are shown in the upper 2 curves. Also shown are the adjusted HRs for respective outcomes using marrow recipients as the reference group. Solid line indicates G-PBMC group; and hyphenated line, bone marrow group.

Close Modal

or Create an Account

Close Modal
Close Modal